Show simple item record

dc.contributor.authorUltsch, Bernhard
dc.contributor.authorWeidemann, Felix
dc.contributor.authorReinhold, Thomas
dc.contributor.authorSiedler, Anette
dc.contributor.authorKrause, Gerard
dc.contributor.authorWichmann, Ole
dc.date.accessioned2015-11-25T15:53:39Zen
dc.date.available2015-11-25T15:53:39Zen
dc.date.issued2013en
dc.identifier.citationHealth economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. 2013, 13:359 BMC Health Serv Resen
dc.identifier.issn1472-6963en
dc.identifier.pmid24070414en
dc.identifier.doi10.1186/1472-6963-13-359en
dc.identifier.urihttp://hdl.handle.net/10033/582736en
dc.description.abstractHerpes zoster (HZ) is a self-limiting painful skin rash affecting mostly individuals from 50 years of age. The main complication is postherpetic neuralgia (PHN), a long-lasting pain after rash has resolved. A HZ-vaccine has recently been licensed in Europe for individuals older than 50 years. To support an informed decision-making for a potential vaccination recommendation, we conducted a health economic evaluation to identify the most cost-effective vaccination strategy.
dc.language.isoenen
dc.subject.meshAgeden
dc.subject.meshAged, 80 and overen
dc.subject.meshCost-Benefit Analysisen
dc.subject.meshFemaleen
dc.subject.meshGermanyen
dc.subject.meshHealth Care Costsen
dc.subject.meshHerpes Zosteren
dc.subject.meshHerpes Zoster Vaccineen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMarkov Chainsen
dc.subject.meshMiddle Ageden
dc.subject.meshModels, Economicen
dc.subject.meshNeuralgia, Postherpeticen
dc.subject.meshQuality-Adjusted Life Yearsen
dc.titleHealth economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.en
dc.typeArticleen
dc.contributor.departmentHelmholtz Centre for infection research, Inhoffenstr. 7, D-38124 Braunschweig, Germany.en
dc.identifier.journalBMC health services researchen
refterms.dateFOA2018-06-13T09:19:42Z
html.description.abstractHerpes zoster (HZ) is a self-limiting painful skin rash affecting mostly individuals from 50 years of age. The main complication is postherpetic neuralgia (PHN), a long-lasting pain after rash has resolved. A HZ-vaccine has recently been licensed in Europe for individuals older than 50 years. To support an informed decision-making for a potential vaccination recommendation, we conducted a health economic evaluation to identify the most cost-effective vaccination strategy.


Files in this item

Thumbnail
Name:
Ultsch et al_final.pdf
Size:
311.1Kb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record